



Stockholm, 2019-04-05

## **PRESS RELEASE**

### **Patent approved in USA**

#### **QuiaPEG Pharmaceuticals Holding AB (publ) receives so-called "Notice of Allowance" on granting of a patent in the United States**

QuiaPEG Pharmaceuticals Holding AB (publ), which develops improved and patentable versions of clinically validated or approved drugs with the help of the company's unique technology platform, announces that the company has received a so-called "Notice of Allowance" from the US Patent Office (USPTO).

For further information contact:

Marcus Bosson

CEO

Tel: +46 (0) 70 693 12 53

E-mail: [marcus.bosson@quiapeg.com](mailto:marcus.bosson@quiapeg.com)

[www.quiapeg.com](http://www.quiapeg.com)

*This information is such that QuiaPEG Pharmaceuticals Holding AB (publ) is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted, through the agency of the above contact person, for publication on April 5, 2019.*